P2X7 is a cytotoxic receptor….maybe not: implications for cancer

Cockcroft S, Gomperts BD (1979) ATP induces nucleotide permeability in rat mast cells. Nature 279:541–542 Mirabelli F, Bellomo G, Nicotera P, Moore M, Orrenius S (1986) Ca2+ homeostasis and cytotoxicity in isolated hepatocytes: studies with extracellular adenosine 5′-triphosphate. J Biochem Toxicol 1:29–39 Steinberg TH, Silverstein SC (1987) Extracellular ATP4- promotes cation fluxes in the J774 mouse macrophage cell line. J Biol Chem 262:3118–3122 Cockcroft S, Gomperts BD (1980) The ATP4- receptor of rat mast cells. Biochem J 188:789–798 Weisman GA, de BK, Pritchard RS (1989) Ionic dependence of the extracellular ATP-induced permeabilization of transformed mouse fibroblasts: role of plasma membrane activities that regulate cell volume. J Cell Physiol 138:375–383 Steinberg TH et al (1987) ATP4- permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J Biol Chem 262:8884–8888 Greenberg S et al (1988) Extracellular nucleotides mediate Ca2+ fluxes in J774 macrophages by two distinct mechanisms. J Biol Chem 263:10337–10343 Di Virgilio F et al (1989) Responses of mouse lymphocytes to extracellular adenosine 5′-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol 143:1955–1960 Di Virgilio F (1998) ATP as a death factor. Biofactors 8:301–303 Di Virgilio F et al (1990) Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Immunol Today 11:274–277 Filippini A et al (1990) Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem 265:334–340 Filippini A, Taffs RE, Sitkovsky MV (1990) Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc Natl Acad Sci U S A 87:8267–8271 Burnstock G (1999) Current status of purinergic signalling in the nervous system. Prog Brain Res 120:3–10 Gordon JL (1986) Extracellular ATP: effects, sources and fate. Biochem J 233:309–319 Di Virgilio F et al (1996) P2 purinoceptors in the immune system. CIBA Found Symp 198:290–302 Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272:735–738 Born GV, Kratzer MA (1984) Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man. J Physiol 354:419–429 Wiley JS, Dubyak GR (1989) Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemic lymphocytes. Blood 73:1316–1323 Wiley JS, Chen R, Jamieson GP (1993) The ATP4- receptor-operated channel (P2Z class) of human lymphocytes allows Ba2+ and ethidium+ uptake: inhibition of fluxes by suramin. Arch Biochem Biophys 305:54–60 Wiley JS, Chen JR, Snook MB, Jamieson GP (1994) The P2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. Br J Pharmacol 112:946–950 Jamieson GP, Snook MB, Thurlow PJ, Wiley JS (1996) Extracellular ATP causes of loss of L-selectin from human lymphocytes via occupancy of P2Z purinocepters. J Cell Physiol 166:637–642 Spranzi E, Djeu JY, Hoffman SL, Epling-Burnette PK, Blanchard DK (1993) Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor. Blood 82:1578–1585 Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, Cuneo A, Castoldi G, di Virgilio F, Baricordi OR (2002) P2X(7) receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99:706–708 White N, Butler PEM, Burnstock G (2005) Human melanomas express functional P2 X(7) receptors. Cell Tissue Res 321:411–418 Rapaport E (1988) Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol 24:1491–1497 Shabbir M, Thompson C, Jarmulowiczc M, Mikhailidis D, Burnstock G (2008) Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU Int 102:108–112 Raffaghello L, Chiozzi P, Falzoni S, di Virgilio F, Pistoia V (2006) The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res 66:907–914 Di Virgilio F et al (2009) P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal 5:251–256 Baricordi O, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E, Rubini M, di Virgilio F (1996) An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 87:682–690 Baricordi O et al (1999) Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem 274:33206–33208 Pizzo P et al (1992) Role of P2z purinergic receptors in ATP-mediated killing of tumor necrosis factor (TNF)-sensitive and TNF-resistant L929 fibroblasts. J Immunol 149:3372–3378 Adinolfi E et al (2005) Basal activation of the P2X(7) ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 16:3260–3272 Adinolfi E, Callegari MG, Cirillo M, Pinton P, Giorgi C, Cavagna D, Rizzuto R, di Virgilio F (2009) Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem 284:10120–10128 Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandonà D, Markwardt F, Schmalzing G, di Virgilio F (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24:3393–3404 Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, di Virgilio F (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72:2957–2969 Burnstock G, Di Virgilio F (2013) Purinergic signalling and cancer. Purinergic Signal 9:491–540 Lara R, Adinolfi E, Harwood CA, Philpott M, Barden JA, di Virgilio F, McNulty S (2020) P2X7 in cancer: from molecular mechanisms to therapeutics. Front Pharmacol 11:793 Di Virgilio F (2012) Purines, purinergic receptors, and cancer. Cancer Res 72:5441–5447 Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293–303 Di Virgilio F et al (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18:601–618 Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170–1178 Kan LK, Williams D, Drummond K, O’Brien T, Monif M (2019) The role of microglia and P2X7 receptors in gliomas. J Neuroimmunol 332:138–146 Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D, Pinton P, Jorgensen NR, Abelli L, Emionite L, Raffaghello L, Pistoia V, di Virgilio F (2015) Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res 75:635–644 De Marchi E et al (2019) The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38:3636–3650 Romagnani A, Rottoli E, Mazza EMC, Rezzonico-Jost T, de Ponte Conti B, Proietti M, Perotti M, Civanelli E, Perruzza L, Catapano AL, Baragetti A, Tenedini E, Tagliafico E, Falzoni S, di Virgilio F, Norata GD, Bicciato S, Grassi F (2020) P2X7 receptor activity limits accumulation of T cells within tumors. Cancer Res, in press 80:3906–3919 Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC (2018) The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8(+) T cells. Nature 559:264–268 Borges da Silva H, Peng C, Wang H, Wanhainen KM, Ma C, Lopez S, Khoruts A, Zhang N, Jameson SC (2020) Sensing of ATP via the purinergic receptor P2RX7 promotes CD8(+) Trm cell generation by enhancing their sensitivity to the cytokine TGF-beta. Immunity 53:158–171e6 Di Virgilio F et al (2018) The elusive P2X7 macropore. Trends Cell Biol 28:392–404 Pellegatti P, Falzoni S, Pinton P, Rizzuto R, di Virgilio F (2005) A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell 16:3659–3665 Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, di Virgilio F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3:e2599 Morciano G, Sarti AC, Marchi S, Missiroli S, Falzoni S, Raffaghello L, Pistoia V, Giorgi C, di Virgilio F, Pinton P (2017) Use of luciferase probes to measure ATP in living cells and animals. Nat Protoc 12:1542–1562 Seman M, Adriouch S, Scheuplein F, Krebs C, Freese D, Glowacki G, Deterre P, Haag F, Koch-Nolte F (2003) NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19:571–582 Linden J, Koch-Nolte F, Dahl G (2019) Purine release, metabolism, and signaling in the inflammatory response. Annu Rev Immunol 37:325–347 Koch-Nolte F, Kernstock S, Mueller-Dieckmann C, Weiss MS, Haag F (2008) Mammalian ADP-ribosyltransferases and ADP-ribosylhydrolases. Front Biosci 13:6716–6729 Di Virgilio F et al (2018) Non-nucleotide agonists triggering P2X7 receptor activation and pore formation. Front Pharmacol 9:39 Helliwell RM, ShioukHuey CO, Dhuna K, Molero JC, Ye JM, Xue CC, Stokes L (2015) Selected ginsenosides of the protopanaxdiol series are novel positive allosteric modulators of P2X7 receptors. Br J Pharmacol 172:3326–3340 Stokes L, Bidula S, Bibič L, Allum E (2020) To inhibit or enhance? Is there a benefit to positive allosteric modulation of P2X receptors? Front Pharmacol 11:627 Elssner A, Duncan M, Gavrilin M, Wewers MD (2004) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 172:4987–4994 Tomasinsig L, Pizzirani C, Skerlavaj B, Pellegatti P, Gulinelli S, Tossi A, Virgilio FD, Zanetti M (2008) The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J Biol Chem 283:30471–30481 Ferrari D, Pizzirani C, Adinolfi E, Forchap S, Sitta B, Turchet L, Falzoni S, Minelli M, Baricordi R, di Virgilio F (2004) The antibiotic polymyxin B modulates P2X7 receptor function. J Immunol 173:4652–4660 Norenberg W et al (2011) Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations. J Biol Chem 286:11067–11081 Coffelt SB, Scandurro AB (2008) Tumors sound the alarmin(s). Cancer Res 68:6482–6485 Kuroda K et al (2015) The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol 5:144 Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14:1–18 Gilbert SM, Gidley Baird A, Glazer S, Barden JA, Glazer A, Teh LC, King J (2017) A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol 177:117–124 Allard B et al (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol in press Sitkovsky MV (2020) Lessons from the A2A adenosine receptor antagonist-enabled tumor regression and survival in patients with treatment-refractory renal cell cancer. Cancer Discov 10:16–19 Galluzzi L et al (2020) Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol in press